Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

CASE REPORT

Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma

Badri Nabeel, Ngamdu Kyari Sumayin, Torabi Alireza, Guar Sumit

Year : 2020| Volume: 16| Issue : 1 | Page no: 183-185

   This article has been cited by
 
1 CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies
Roland Schwarting, Eric Behling, Ashleigh Allen, Vivian Arguello-Guerra, Tulin Budak-Alpdogan
Archives of Pathology & Laboratory Medicine. 2022; 146(4): 415
[Pubmed]  [Google Scholar] [DOI]
2 Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
Sundar V Cherukuri, Amit Sureen, Taylor Infante, Nevetha Rajendran, Osvaldo Padilla, Sumit Gaur
Cureus. 2021;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article